Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI3003 and Daratumumab in Multiple Myeloma
NCT07764861Phase 2Not yet recruiting
- Sponsor
- Innovent Biologics
- Start
- Aug 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
A Phase 2 trial of IBI3003 in multiple myeloma (MM), sponsored by Innovent Biologics. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
IBI3003
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07764861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07764861.